

Table of Contents from a previously issued report

Interim Report Assumptions - Specialty Distribution Options for Orphan Drug Q	0
Basic Background and Definitions (US Market)	0
Specialty Pharmacy Distribution Providers (SP or SPP)	0
Payer (also Payor)	0
Pharmacy Benefit Manager (PBM)	0
Patient services/SP services or “hub” (also HUB)	0
Hub Patient Care process overview	0
Commercially Valuable Data from Specialty Pharmacy Distribution	0
Definition of closed, limited and open networks (Specialty distribution models)	0
Wholesale and retail specialty drug distribution	0
Third party logistics (3PL), The Hospital/Institutional Market Segment	00
REMS (Risk Evaluation and Mitigation Strategies)	00
Nurse educators and home nurse network	00
Patient Access programs and Patient assistance	00
Patient Health Information (PHI) – HIPAA and HITECH	00
Disaster recovery/business continuity	00
Putting it all together – basic Specialty distribution overview	00
Putting it all together – Specialty Pharmacy HUB Specialists	00
Patient Care Coordinators/Specialists	00
Reimbursement Specialists	00
Clinical Support Specialists	00
Strategic Considerations	00
Build in-house hub/SP capability?	00
Closed versus limited/open distribution – external/market factors	00
Distribution Network – Unique orphan Market and product characteristics	00
Proportion of Specialty “retail” vs. “wholesale” (3PL/institutional) distribution	00
Potential vendor (SP And HUB) positions on open – Closed distribution	00
Skeptics on the long-term feasibility of a closed Distribution model	00
Advocates for a limited/open Specialty Pharmacy Distribution Network	00
Additional input on closed distribution - ultra-orphan conference	00
Patient Access and Model Choice – Additional perspectives	00
Basic Orphan Drug Launch Access/Reimbursement Consensus	00
What patient programs might improve launch access regardless of scenario?	00
Closed model – launch predictions concerning Orphan Drug access	00
Potential US Specialty Pharmacy/ Hub Partners Reviewed to-date	00
US Partner/vendor options overview	00
PBM-owned specialty pharmacy – the “Big 3” as a group	00
Services offered by the “Big 3” – as a group	00
Large specialty pharmacy distributors owned by wholesalers	00
Small independents	00
Wholesale distribution to hospitals/institutions and 3PL	00

Optio Biotech Consulting, LLC
Biopharmaceutical Industry Commercial & Marketing Services
www.OptioLLC.com

Individual vendors – Differentiating Characteristics	00
Accredo	00
Curascript	00
CVS/Caremark	00
Centric Health	00
US Bioservices	00
Premier Source	00
McKesson (3PL)	00
Walgreens	00
Other US vendors under review	00
Vendor capabilities Overview Matrix	00
Summary of Key Findings	00
Key findings – United States	00
Key findings - Europe and ROW (EU & ROW SP Distribution section removed from this excerpt)	